Dangshe Ma

I am a Senior Director at Regeneron Pharmaceuticals, where I lead a team focused on Antibody Radionuclide Conjugates (ARC) for targeted imaging and therapeutic applications. I earned my Ph.D. in Radiopharmaceutical Chemistry from the University of Missouri–Columbia and completed postdoctoral training at Memorial Sloan Kettering Cancer Center, where I contributed to pioneering work on DOTA chelation for Ac-225 and co-authored a 2001 Science paper describing the in vivo Ac-225/Bi-213 nanogenerator. Throughout my career at Progenics, Pfizer, and Regeneron, I have advanced antibody-based therapies—including Antibody-Drug Conjugates (ADC) and ARC—from early research into clinical development.